Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: Business Wire
- Studies include quantitative findings from patients and healthcare professionals, and new perspectives on somatostatin analogs in the management of neuroendocrine tumors (NETs) and acromegaly- Multinational PRESTO (nurse preference) study results simultaneously published as open access in peer-reviewed medical journal, Advances in Therapy- Presentations showcase Ipsen’s commitment to patient centricity, multi-stakeholder collaboration PARIS--(BUSINESS WIRE)--Regulatory News:Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of 13 new abstracts 1 during the 17 th European Neuroendocrine Tumor Society (ENETS) Annual Conference, taking place virtually worldwide, (March 11-13, 2020) and the simultaneous publication of the PRESTO study in the medical journal, Advances in Therapy. 2 These data reinforce Ipsen’s personal approach to working with patients living with neuroendocrine tumors (NETs) and acromegaly, and healthcare professionals treating these conditions.NETs a
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSGlobeNewswire
- Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritusGlobeNewswire
- Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidanceGlobeNewswire
- Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver diseaseGlobeNewswire
- Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decadeGlobeNewswire